Caitong International Asset Management’s Chemomab Therapeutics CMMB Stock Holding History

Caitong International Asset Management’s Portfolio CMMB Stock Details CMMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13	Buy	+8	New	+$14	﹤0.01%	2112

Other funds holding CMMB

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KPWS

Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $240M AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

PIP

Philadelphia Investment Partners Voorhees, New Jersey $147M AUM

Caitong International Asset Management's CMMB Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Chemomab Therapeutics (CMMB) in Q1 2026: 8 shares worth $13. The stake represents ﹤0.01% of the portfolio and ranks #2112 among its holdings.

15 funds tracked by Wall St. Rank hold CMMB as of Q1 2026.

Caitong International Asset Management held 8 shares of Chemomab Therapeutics worth $13 as of Q1 2026.
Chemomab Therapeutics was a new Caitong International Asset Management position in Q1 2026.
Chemomab Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2112 holding.
15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.